Navigation Links
NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference

Data demonstrates that NewCardio's platform technology delivers new levels of analysis of heart's electrical activity

SANTA CLARA, Calif., May 18 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today announced that members of the Company's medical and technology teams presented two abstracts and discussed new clinical data from analytical and clinical applications of its proprietary platform technology at The Heart Rhythm Society (HRS) 30th Annual Scientific Sessions on May 13-16, 2009 in Boston, MA.

NewCardio introduced the NewCardio platform, QTinno(TM) and Visual3Dx(TM), at Heart Rhythm 2009 30th Annual Scientific Sessions. The Company believes that its QTinno(TM), software-based, analytical technology is the industry's first solution for the reliable automated analysis of ECGs used to determine cardiac toxicity during drug development. Visual3Dx(TM) will generate 3D information from the heart using standard 12-lead ECG data. It is expected to provide clinicians additional information on the extent and localization of acute ischemic insult to the heart to improve the speed and accuracy of diagnosis of Acute Coronary Syndrome.

HRS is the international leader in science, education and advocacy for cardiac arrhythmia professionals and patients, and the primary information resource on heart rhythm disorders. Its mission is to improve the care of patients by promoting research, education and optimal health care policies and standards. The Annual Scientific Sessions attract more than 9,000 professionals representing the allied specialties of cardiac pacing and cardiac electrophysiology. More information is available at on the Internet.

The two abstracts presented were:

"Vectorcardiographic Evidence of Cardiac Memory During Continuous Ventricular Pacing," authored by Drs. Alexei Shvilkin, Mark Josephson and Peter Zimetbaum, all of the Department of Medicine/Division of Cardiology at the Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, as well as Drs. Bosko Bojovic (NewCardio's co-founder and senior consultant), Branislav Vajdic (NewCardio's Chief Executive Officer), and Ihor Gussak (NewCardio's Chief Medical Officer). This study presents data demonstrating the ability to identify cardiac memory (post-pacing T wave abnormality) during continuous ventricular pacing using the Company's 3-dimensional ECG interpretation tools. Previously, this phenomenon was only described in the setting of a return to normal ventricular activation. This observation advances our understanding of wide complex rhythms physiology and serves as a basis for improving ECG diagnosis in the setting of abnormal ventricular activation (left bundle branch block (LBBB) and ventricular pacing).

"Vectorcardiographic Discrimination Between Acute and Chronic Left Bundle Branch Block," authored by Drs. Shvilkin, Josephson and Zimetbaum from the Beth Israel Deaconess Medical Center/Harvard Medical School, as well as Drs. Bojovic, Vajdic and Gussak. The study demonstrates that by using NewCardio's platform technology, it is possible to distinguish new onset left bundle branch block (LBBB) from a chronic one. This constitutes a significant diagnostic advance in a setting of acute coronary syndrome (ACS). Currently, new or presumed new onset LBBB is a Class I indication for primary percutaneous coronary intervention or fibrinolytic therapy in patients presenting with symptoms consistent with ACS. Up until now there have been no diagnostic criteria to distinguish new onset from chronic LBBB and if no prior ECGs were available it had to be presumed "new." NewCardio technology allows the reader to determine the duration of LBBB without previous ECG tracings. This finding can potentially reduce the number of unnecessary coronary interventions.

Branislav Vajdic, PhD, NewCardio's Chief Executive Officer, commented, "These two abstracts clearly demonstrate the power of NewCardio's platform technology in difficult clinical settings. This solution enables doctors to obtain much more clinically relevant information than previous technologies allowed, setting the stage for clinical advances which have the potential to save lives by more rapidly and accurately diagnosing cardiac events. We are excited to have had the opportunity to discuss these findings at the Heart Rhythm Society conference, the premier gathering for the electrophysiology community."

About NewCardio, Inc.

NewCardio is a cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio's development-stage software and hardware products and services are intended to improve the diagnosis and monitoring of cardiovascular disease (CVD), as well as cardiac safety assessment of drugs under development. NewCardio's three-dimensional ECG platform is designed to reduce the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. For more information, visit

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2008 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.

To join our email distribution please click this link:

    Investor Contact:
    Hayden IR
    Jeff Stanlis
    Partner and Vice President of Communications
    (602) 476-1821

SOURCE NewCardio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NewCardio Announces New Client Services Team
2. NewCardio Restructures 2007 Financing, Receives $2.8 Million Additional Cash and Improves Capital Structure
3. NewCardio to Present at OneMedForum 2009: Disrupters and Drivers on January 13 in San Francisco
4. NewCardio Leadership to Present Clinical Data of Fully Automated QTinno(TM) Study at American College of Cardiology Annual Meeting
5. UPDATE: NewCardio Leadership to Present Clinical Data of Fully Automated QTinno(TM) Study at American College of Cardiology Annual Meeting
6. NewCardio Elects Michael E. Hanson to Board of Directors
7. NewCardio Leadership to Make Two Presentations at Drug Information Association Drug Safety Conference
8. NewCardio to Introduce Technology at Heart Rhythm Society Conference
9. MSU engineering team designs innovative medical device
10. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
11. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
Post Your Comments:
(Date:10/13/2015)... ... 13, 2015 , ... According to an article published October 5th ... who successfully lose weight with a bariatric procedure are much less likely to develop ... notes that anywhere from 40 to 50 percent of all endometrial cancer cases are ...
(Date:10/13/2015)... , ... October 13, 2015 , ... Symposium Chairman, Dr. ... 19th annual Dallas Cosmetic Symposium to be held March 2nd and 3rd, 2016. The ... afterwards, draws plastic surgeons and cosmetic physicians from around the world. , Key topics ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... unique private messaging application, announced today a significant contract that will provide its ... Independence plans to build on the growing success of its Relay program, IBX ...
(Date:10/13/2015)... ... ... NavaFit Inc. today announced the launch of its NavaFit app for iPhone® ... fitness & sporting events, and stay motivated. Users can download the apps ... to get more serious about fitness and wellness, individuals are constantly looking for new ...
(Date:10/13/2015)... ... 2015 , ... Protein is essential to good health. You need it to ... how much protein does the average man need in order to stay healthy? ... 2015 issue of Harvard Men's Health Watch . Most Americans get about 15% ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... Given the intricacy of the anatomy and physiology of ... drug effectively to a specific ocular site. Several barriers have ... include dilution of a drug by tears, clearance of a ... issues with respect to the cornea, sclera and choroid. Approximately ... due to the aforementioned barriers. --> Given ...
(Date:10/12/2015)... 12, 2015  Former White House Spokesman, and Drug Czar ... House Narcotics Committee, Robert Weiner , and Policy Analyst ... two emphasize that this is now a potential bipartisan campaign ... Jeb Bush , Carly Fiorina to Rand ... federal statistics, which they call "a shocker: 23 million need ...
(Date:10/12/2015)... 2015  Luminex Corporation (NASDAQ: LMNX ) today announced ... ended September 30, 2015 on Monday, November 2, 2015. A ... the close of trading. --> ... discuss the operating highlights and financial results for the third ... 4:30 p.m. Eastern time. . Simply ...
Breaking Medicine Technology: